Hybrid imaging of neuroendocrine tumors in the heart: Union is strength

J Nucl Cardiol. 2023 Feb;30(1):298-312. doi: 10.1007/s12350-021-02804-6. Epub 2021 Oct 7.

Abstract

Cardiac neuroendocrine tumors (NETs) are particularly rare tumors that can lead to a very poor clinical outcome, partly because of metastases but mainly because of manifestations of the hormonal activity they exhibit. Prompt diagnosis is important in order to start the most effective treatment for their removal or management, with the fewest complications. They are often difficult to diagnose, especially in their early stages. One of the reasons for this is that the heart is an organ with a high rate of metabolism and is located in close proximity to other high-metabolism organs. In addition, the anatomic location and their small size render their diagnosis extremely challenging. In recent years, hybrid imaging methods have revolutionized the diagnostic approach to oncology patients and have established a place in the diagnosis of cardiac NETs, because they provide both anatomical and functional information at the same time. Positron emission tomography/computed tomography (PET/CT), PET/magnetic resonance imaging (PET/MRI) and single-photon emission computed tomography/CT (SPECT/CT) are widely used in clinical practice because of the very important metabolic information, the high sensitivity and specificity. However, prospective studies are needed to confirm the true clinical and prognostic value of various hybrid imaging diagnostic techniques in cardiac NETs.

Keywords: Hybrid imaging; tests; tracers.

Publication types

  • Review

MeSH terms

  • Heart Neoplasms*
  • Humans
  • Multimodal Imaging
  • Neuroendocrine Tumors*
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography / methods
  • Tomography, Emission-Computed, Single-Photon